ArticleAJOG global reports2026
Hyperpyrexia with hemodynamic instability after sublingual misoprostol: case report and literature review.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Misoprostol is widely used in obstetric practice for the prevention and treatment of postpartum hemorrhage due to its uterotonic efficacy, oral administration, and stability at room temperature. Although generally considered safe, rare but severe adverse reactions have been reported. We present the case of a 27-year-old woman who developed hyperpyrexia (41°C), hemodynamic instability, hypoxemia, and generalized seizures shortly after receiving 1000 µg of sublingual misoprostol for postpartum uterine atony. Life-threatening differential diagnoses, including sepsis, pulmonary thromboembolism, eclampsia, and amniotic fluid embolism, were excluded. The patient required intensive supportive care, with complete clinical recovery and no sequelae. A review of the literature shows that similar cases are uncommon but share features such as sublingual administration, high doses, and a self-limited course with supportive management. This report highlights the importance of recognizing misoprostol-induced hyperpyrexia to guide appropriate management and avoid unnecessary interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.